Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to loss of$0.68 per share a year ago. These figures are adjusted for non- recurring items. A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.47 per share when it actually produced a loss of$0.43, delivering a surprise of 8.51%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Allogene Therap ...